To assess the longitudinal effect of cyclophosphamide (CYC) treatment on type-I interferon (IFN) signature in proliferative lupus nephritis (LN) and its role in predicting treatment response.
Methods
Fifty-four biopsy proven proliferative LN patients scheduled to receive high-dose (HD) or low-dose (LD) CYC were recruited and followed up for six months. At six months, patients were classified as clinical responders (CR) or non-responders (NR) to treatment, using the EULAR/EDTA criteria. An IFN-gene based score (IGS) was developed from the mean log-transformed gene expression of MX1, OAS1, IFIT1, OASL, IFIT4, LY6E, IRF7 at baseline, three and six months. Longitudinal changes of IGS within and between groups were assessed and ΔIGS, which is the difference in IGS between baseline and three months was calculated. Independent predictors of non-response were identified and an ROC analysis was performed to evaluate their utility to predict NR.
Results
There was a dynamic change in IGS within the HD, LD, CR, and NR groups. Compared to baseline, there was a significant decrease in IGS at three months in HD and LD groups (HD group: 2.01 to 1.14, p = .001; LD group = 2.01 to 0.81, p < .001), followed by a significant increase from three to six months in LD group (LD: 0.81 to 1.51, p = .03; HD: 1.14 to 1.54, p = .300). A decrease in IGS from baseline to three months was seen in both CR (2.13 to 0.79, p < .001) and NR groups (1.83 to 1.27, p = .046), and a significant increase from three to six months was observed only in the CR group (CR: 0.79 to 1.57, p = .006; NR: 1.27 to 1.46, p = 1). ΔIGS (baseline to three months) was higher in CR compared to NR group (−1.339 vs −0.563, p = .017). ROC analysis showed that the model comprising of 0.81 fold decrease in IGS from baseline to three months, endocapillary hypercellularity and interstitial inflammation on renal histopathology predicted non-response with a sensitivity of 83.3% and specificity of 71.4%.
Conclusion
In proliferative LN, treated with HD or LD-CYC, combined model comprising of decrease in IGS score by 0.81 fold from baseline to three months, along with important histopathological features such as endocapillary hypercellularity and interstitial inflammation had better predictive capability for non-response.
CrocaSCRodriguesTIsenbergDA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology2011; 50(8): 1424–1430.
2.
ChenYSunJZouK, et al.Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses. Rheumatol Int2017; 37(7): 1089–1099.
3.
TektonidouMGDasguptaAWardMM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a Systematic review and bayesian meta-analysis. Arthritis Rheumatol2016; 68(6): 1432–1441.
4.
DingXRenYHeX. IFN-I mediates lupus nephritis from the beginning to renal fibrosis. Front Immunol2021; 12: 676082.
5.
PostalMVivaldoJFFernandez-RuizR, et al.Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol2020; 67: 87–94.
BonALSchiavoniGD’AgostinoG, et al.Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity2001; 14(4): 461–470.
8.
HanGMChenSLShenN, et al.Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray. Gene Immun2003; 4(3): 177–186.
9.
BaechlerECBatliwallaFMKarypisG, et al.Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA2003; 100(5): 2610–2615.
10.
BennettLPaluckaAKArceE, et al.Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med2003; 197(6): 711–723.
11.
FengDStoneRCProgramM, et al.Genetic variants and disease-associated factors contribute to enhanced IRF-5 expression in blood cells of systemic lupus erythematosus patients. Arthritis Rheum2010; 62(2): 562–573.
12.
KirouKALeeCGeorgeS, et al.Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum2005; 52(5): 1491–1503.
13.
ParikhSVMalvarASongH, et al.Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis. Kidney Int2022; 102(4): 845–865.
14.
BanchereauRHongSCantarelB, et al.Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell2016; 165(3): 551–565.
15.
VitalEMMerrillJTMorandEF, et al.Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis2022; 25: 221425.
16.
WilkinsonCHendersonRBJones-LeoneAR, et al.The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis. Arthritis Res Ther2020; 22: 102.
17.
KhamashtaMMerrillJTWerthVP, et al.Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis2016; 75(11): 1909–1916.
18.
FanouriakisAKostopoulouMAndersenJ, et al.EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis2024; 83(1): 15–29.
19.
FanouriakisATziolosNBertsiasG, et al.Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis2021; 80(1): 14–25.
20.
MehraSUsdadiyaJBJainVK, et al.Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study. Rheumatol Int2018; 38(4): 557–568.
21.
KongKOTanAWThongBYH, et al.Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus. Clin Exp Immunol2009; 156(1): 134–140.
22.
BauerJWPetriMBatliwallaFM, et al.Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum2009; 60(10): 3098–3107.
23.
SiddiqiKZZinglersenAHIversenKK, et al.A cluster of type II interferon-regulated genes associates with disease activity in patients with systemic lupus erythematosus. J Autoimmun2022; 132: 102869.
24.
NorthcottMJonesSKoelmeyerR, et al.Type 1 interferon status in systemic lupus erythematosus: a longitudinal analysis. Lupus Science & Medicine2022; 9(1): e000625.
25.
BarturenGBabaeiSCatalà-MollF, et al.Integrative analysis reveals a molecular stratification of systemic autoimmune diseases. Arthritis Rheumatol2021; 73(6): 1073–1085.
26.
El-SherbinyYMMd YusofMYPsarrasA, et al.B cell tetherin: a flow cytometric cell-specific assay for response to type I interferon predicts clinical features and flares in systemic lupus erythematosus. Arthritis Rheumatol2020; 72(5): 769–779.
27.
HongSBanchereauRMaslowBSL, et al.Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. J Exp Med2019; 216(5): 1154–1169.
28.
RoseTGrützkauAKlotscheJ, et al.Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology2017; 56(9): 1618–1626.
29.
ConnellyKLKandane-RathnayakeRHuqM, et al.Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus. Sci Rep2018; 8(1): 3268.
30.
CrowMKWohlgemuthJ. Microarray analysis of gene expression in lupus. Arthritis Res Ther2003; 5(6): 279–287.
31.
FengXWuHGrossmanJM, et al.Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. Arthritis Rheum2006; 54(9): 2951–2962.
32.
FengXHuangJLiuY, et al.Identification of interferon-inducible genes as diagnostic biomarker for systemic lupus erythematosus. Clin Rheumatol2015; 34(1): 71–79.
33.
Numajiri HarukiANaitoTNishieT, et al.Interferon-inducible antiviral protein MxA enhances cell death triggered by endoplasmic reticulum stress. J Interferon Cytokine Res2011; 31(11): 847–856.
34.
ZhuJGhoshASarkarSN. OASL—a new player in controlling antiviral innate immunity. Current Opinion in Virology2015; 12: 15–19.
35.
YeS. Protein interaction for an interferon-inducible systemic lupus associated gene, IFIT1. Rheumatology2003; 42(10): 1155–1163.
36.
HuangXShenNBaoC, et al.Interferon-induced protein IFIT4 is associated with systemic lupus erythematosus and promotes differentiation of monocytes into dendritic cell-like cells. Arthritis Res Ther2008; 10(4): R91.
37.
PflughDLMaherSEBothwellALM. Ly-6 superfamily members ly-6A/E, ly-6C, and ly-6I recognize two potential ligands expressed by B lymphocytes. J Immunol2002; 169(9): 5130–5316.
38.
BajemaIMWilhelmusSAlpersCE, et al.Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int2018; 93(4): 789–796.
BoumpasDTAustinHABalowJE, et al.Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet1992; 340(8822): 741–745.
41.
Ruiz-IrastorzaGDanzaAPeralesI, et al.Prednisone in lupus nephritis: how much is enough?Autoimmun Rev2014; 13(2): 206–214.
42.
FanouriakisAKostopoulouMCheemaK, et al.Update of the oint European league against rheumatism and European renal association-European Dialysis and transplant association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis2020; 79(6): 713–723.
43.
WahadatMJSchonenberg-MeinemaDvan Helden-MeeuwsenCG, et al.Gene signature fingerprints stratify SLE patients in groups with similar biological disease profiles: a multicenter longitudinal study. Rheumatology2022; 61: keac083.
44.
ChicheLJourde-ChicheNWhalenE, et al.Modular transcriptional repertoire analyses of adults with systemic lupus erythematosus reveal distinct type I and type II interferon signatures. Arthritis Rheumatol2014; 66(6): 1583–1595.
45.
Landolt-MarticorenaCBonventiGLubovichA, et al.Lack of association between the interferon-α signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis2009; 68(9): 1440–1446.
46.
ShobhaVMohanAMaliniAV, et al.Identification and stratification of systemic lupus erythematosus patients into two transcriptionally distinct clusters based on IFN-I signature. Lupus2021; 30(5): 762–774.
47.
NorthcottMGearingLJNimHT, et al.Glucocorticoid gene signatures in systemic lupus erythematosus and the effects of type I interferon: a cross-sectional and in-vitro study. The Lancet Rheumatology2021; 3(5): e357–e370.
48.
NatarajaCFlynnJDankersW, et al.GILZ regulates type I interferon release and sequesters STAT1. J Autoimmun2022; 131: 102858.
49.
MaiLAsaduzzamanANoamaniB, et al.The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. Arthritis Res Ther2021; 23(1): 29.
50.
GopalAKavadichandaCBairwaD, et al.Performance of clinical and biochemical parameters in identifying renal histopathology and predictors of one-year renal outcome in lupus nephritis-A single centre study from India. Diagnostics2022; 12(12): 3163.
51.
FavaABuyonJMagderL, et al.Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight2024; 9(2): e172569.
52.
MorandEFFurieRTanakaY, et al.Trial of Anifrolumab in active systemic lupus erythematosus. N Engl J Med2020; 382(3): 211–221.
53.
CederbladBBlombergSVallinH, et al.Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-alpha- producing cells. J Autoimmun1998; 11(5): 465–470.
54.
RoderoMPDecalfJBondetV, et al.Detection of interferon alpha protein reveals differential levels and cellular sources in disease. J Exp Med2017; 214(5): 1547–1555.
55.
OkeVGunnarssonIDorschnerJ, et al.High levels of circulating interferons type I, type II and type III associate with distinct clinical features of active systemic lupus erythematosus. Arthritis Res Ther2019; 21: 107.
56.
YerramKVBaisyaRKumarP, et al.Serum interferon-alpha predicts in-hospital mortality in patients hospitalised with acute severe lupus. Lupus Sci Med2023; 10(2): e000933.
57.
LyonsPAMcKinneyEFRaynerTF, et al.Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis. Ann Rheum Dis2010; 69(6): 1208–1213.
58.
BeckerAMDaoKHHanBK, et al.SLE peripheral blood B cell, T cell and myeloid cell transcriptomes display unique profiles and each subset contributes to the interferon signature. PLoS One [Internet]2013; 8(6): e67003. Available fromhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691135/
59.
FlintSMJovanovicVTeoBW, et al.Leucocyte subset-specific type 1 interferon signatures in SLE and other immune-mediated diseases. RMD Open2016; 2(1): e000183.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
